Literature DB >> 18398296

Protective immunity following vaccination: how is it defined?

Ian J Amanna1, Ilhem Messaoudi, Mark K Slifka.   

Abstract

Vaccination represents an important medical breakthrough pioneered by Edward Jenner over 200 years ago when he developed the world's first vaccine against smallpox. To this day, vaccination remains the most effective means available for combating infectious disease. There are currently over 20 vaccines licensed for use within the US with many more vaccines in the R&D pipeline. Although vaccines must demonstrate clinical efficacy in order to receive FDA approval, the correlates of immunity vary remarkably between different vaccines and may be based primarily on animal studies, clinical evidence, or a combination of these sources of information. Correlates of protection are critical for measuring vaccine efficacy but researchers should know the history and limitations of these values. As vaccine technologies advance, the way in which we measure and define protective correlates may need to evolve as well. Here, we describe the correlates of protective immunity for vaccines against smallpox, tetanus, yellow fever and measles and compare these to a more recently introduced vaccine against varicella zoster virus, wherein a strict correlate of immunity has yet to be fully defined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398296      PMCID: PMC6776428          DOI: 10.4161/hv.4.4.5751

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  25 in total

1.  Durability of vaccinia immunization based on reaction at the rechallenge site.

Authors:  Michael Sauri; Christopher Sibley; Brenda Monk; Mary Nichols; Shenghan Lai
Journal:  Md Med       Date:  2002

2.  STUDIES ON IMMUNITY TO MEASLES.

Authors:  S KRUGMAN; J P GILES; H FRIEDMAN; S STONE
Journal:  J Pediatr       Date:  1965-03       Impact factor: 4.406

3.  The uses and results of active tetanus immunization.

Authors:  I SCHEIBEL
Journal:  Bull World Health Organ       Date:  1955       Impact factor: 9.408

4.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

5.  Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.

Authors:  C J White; B J Kuter; C S Hildebrand; K L Isganitis; H Matthews; W J Miller; P J Provost; R W Ellis; R J Gerety; G B Calandra
Journal:  Pediatrics       Date:  1991-05       Impact factor: 7.124

6.  A prospective study of serum antibody and protection against smallpox.

Authors:  T M Mack; J Noble; D B Thomas
Journal:  Am J Trop Med Hyg       Date:  1972-03       Impact factor: 2.345

Review 7.  Simian varicella: a model for human varicella-zoster virus infections.

Authors:  Wayne L Gray
Journal:  Rev Med Virol       Date:  2004 Nov-Dec       Impact factor: 6.989

8.  Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Authors:  Thomas P Monath; Richard Nichols; W Tad Archambault; Linda Moore; Ron Marchesani; Jason Tian; Robert E Shope; Nicola Thomas; Robert Schrader; Dean Furby; Philip Bedford
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

9.  Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Authors:  Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

10.  Loss of vaccine-induced immunity to varicella over time.

Authors:  Sandra S Chaves; Paul Gargiullo; John X Zhang; Rachel Civen; Dalya Guris; Laurene Mascola; Jane F Seward
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

View more
  48 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 3.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Authors:  Benjamin J Umlauf; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

Review 5.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 6.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

7.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

Review 8.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

9.  Measurements of immune responses for establishing correlates of vaccine protection against HIV.

Authors:  Wendy A Burgers; Amapola Manrique; David Masopust; Lyle R McKinnon; Matthew R Reynolds; Morgane Rolland; Catherine Blish; Gerald K Chege; Rhonda Curran; William Fischer; Carolina Herrera; D Noah Sather
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

10.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.